Chronic Idiopathic Urticaria (CIU) Treatment Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Chronic Idiopathic Urticaria (CIU) Treatment Market is segmented By Route of Administration (Subcutaneous, Intravenous, Oral), By Molecule Type (Monoclonal Antibody, Small Molecule, Recombinant Fusion Proteins), By Product Type (Mono, Combination), By Development Phase (Phase I, Phase II, Phase III), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Chronic Idiopathic Urticaria (CIU) Treatment Market Size
Taille du Marché en USD Bn
TCAC8%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 8% |
| Concentration du Marché | High |
| Principaux Acteurs | Taizhou Mabtech Pharmaceutical Co. Ltd., Celldex Therapeutics, Allakos, Novartis, GlaxoSmithKline and Among Others. |
please let us know !
Chronic Idiopathic Urticaria (CIU) Treatment Market Analysis
The Chronic Idiopathic Urticaria (CIU) treatment market is estimated to be valued at USD 15.12 Bn in 2024 and is expected to reach USD 25.91 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8% from 2024 to 2031.
There is continuous development of innovative and effective drugs for treating chronic idiopathic urticaria. Furthermore, rising prevalence of chronic idiopathic urticaria worldwide due to increasing environmental pollution and allergens is expected to drive the demand for effective CIU treatments.